Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 26, 2010British Journal of Clinical PharmacologyOpen Access

Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy

View Full Paper
Ask AI
Bookmark
Share

Authors

TBTiphaine Adam de BeaumaisInstitut Gustave RoussyMFMay FakhourySaint Joseph UniversityYMYves MédardAssistance Publique – Hôpitaux de Paris

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Beaumais et al. (2010) studied this question.

synapsesocial.com/papers/6a8a56cb5edafe343d931370https://doi.org/10.1111/j.1365-2125.2010.03867.x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Serum aminotransferase elevation during and following treatment of childhood acute lymphoblastic leukemia.1997 · 53 citations
  2. 2The Purine Path to Chemotherapy1989 · 682 citations
  3. 3Unexpectedly severe toxicity from intensive early treatment of childhood lymphoblastic leukemia.1985 · 38 citations
  4. 4Polyglutamation of methotrexate. Is methotrexate a prodrug?1985 · 468 citations
  5. 5Genetic polymorphism of inosine-triphosphate-pyrophosphatase influences mercaptopurine metabolism and toxicity during treatment of acute lymphoblastic leukemia individualized for thiopurine-S-methyl-transferase status2009 · 56 citations